Skip to main content

Table 1 Characteristics of patients according to 30-day mortality

From: Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: a prospective observational study

 

30-day mortality

Variable

Yes (n = 56)

No (n = 94)

P

Age (years)

66.4 ± 18.4

60.4 ± 17.9

0.38

Sex (male)

42 (75.0)

63 (67.0)

0.40

Charlson score

4 (2–6)

3 (2–6)

0.15

Comorbidities

   

   Neurological

14 (48.3)

44 (36.4)

0.33

   Cardiac

20 (69.0)

69 (57.0)

0.33

   Pulmonary

12 (41.4)

55 (45.5)

0.85

   Malignancy

6 (20.7)

21 (17.4)

0.88

   Diabetes

10 (34.5)

29 (24.0)

0.36

   Renal

4 (13.8)

28 (23.1)

0.20

   Cirrhosis

4 (13.8)

12 (9.9)

0.37

   AIDS

2 (6.9)

8 (6.6)

0.61

Immunosuppression

23 (41.1)

33 (35.5)

0.58

Other infections

17 (30.4)

25 (26.6)

0.76

Previous surgery

24 (42.9)

38 (40.4)

0.90

Length of hospital stay (days)

16.5 (7.5–30)

15.5 (5–30)

0.52

Severe sepsis or septic shock

40 (71.4)

31 (33.0)

<0.001

Ventilator-associated pneumonia

33 (58.9)

22 (23.4)

<0.001

>1 site

7 (12.5)

15 (16.0)

0.73

Polymicrobial pneumonia

23 (41.1)

30 (31.9)

0.38

Bacteremia

12 (21.4)

9 (9.6)

<0.05

Appropriate therapy

   

   At any moment

31 (55.5)

78 (83.0)

<0.001

   ≤ 24 hours

11 (19.6)

35 (37.2)

<0.05

Time to initiate appropriate therapy (days)

4.5 ± 2.1

5.1 ± 5.1

0.60

Combination therapy (n = 109)

3 (9.7)

15 (19.9)

0.18

  1. Data presented as the mean ± standard deviation, as the median (interquartile range), or as n (%).